Juan Galvez, MD
Endocrinology, Diabetes & Metabolism · Tucson, AZNPI 1609050095
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 23 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 10 manufacturers, the largest accounting for just 23.8% — the pattern of someone who eats at a lot of different presentations. That places this record below the midpoint for endocrinology, diabetes & metabolism clinicians in AZ, where the typical reported total is $2,225.
Across 23 payments — averaging $30.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Heartflow, Inc.$167
- Sanofi-aventis U.S. LLC$160
- Insulet Corporation$86
- Novo Nordisk$70
- Dexcom, Inc.$56
- Ascendis Pharma Endocrinology Inc$54
- plus $106 from 4 others
Across 6 payments — averaging $4826.64 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$28K
- Shire North American Group Inc$1K
What the payments were for
- Food & beverage$699100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Heartflow, Inc. | 2 | $167 |
| Sanofi-aventis U.S. LLC | 2 | $160 |
| Insulet Corporation | 4 | $86 |
| Novo Nordisk | 4 | $70 |
| Dexcom, Inc. | 2 | $56 |
| Ascendis Pharma Endocrinology Inc | 2 | $54 |
| AstraZeneca | 3 | $44 |
| Abbott | 2 | $31 |
| Lilly USA, LLC | 1 | $15 |
| Orthogenrx Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$699 in reported general payments places this provider in the 30th percentile of 148 endocrinology, diabetes & metabolism providers in Arizona.
See all endocrinology, diabetes & metabolism providers in Arizona →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 278 | $381,680 |
| OzempicSemaglutide | 157 | $212,708 |
| JardianceEmpagliflozin | 129 | $201,556 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 93 | $134,422 |
| TrulicityDulaglutide | 80 | $127,033 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 39 | $63,834 |
| FarxigaDapagliflozin Propanediol | 42 | $61,287 |
| Tresiba Flextouch U-200Insulin Degludec | 25 | $53,301 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 19 | $24,490 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 13 | $22,477 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 114 | $20,861 |
| ProliaDenosumab | 12 | $20,772 |
| InvokanaCanagliflozin | 13 | $20,434 |
| JanuviaSitagliptin Phosphate | 15 | $19,384 |
| Tresiba Flextouch U-100Insulin Degludec | 21 | $17,942 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity, Humalog, Insulin Lispro | $15 | $517,249397 claims |
| Novo NordiskOzempic | $70 | $212,708157 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33, Lantus | $160 | $136,942105 claims |
| AstraZenecaFarxiga | $44 | $61,28742 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 148 endocrinology, diabetes & metabolism providers in Arizona.
Other endocrinology, diabetes & metabolism in Tucson
- Muhammad SethiTucson$670K
- Karen HerbstTucson$200K
- Nora BarsonyTucson$121K
- Maria PosadasTucson$24K
- Dorota PucykTucson$15K
- Neda EbrahimiTucson$11K
- Casey RendonTucson$9K
- Jonathan InselTucson$7K
- Roshanak HabibiTucson$7K
- Ramiro Cardenas LaraTucson$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.